Locations
San Francisco, CA, USA
industry
Biotechnology
Size
51 - 200 employees
Stage
Series B
founded in
2018
T-Knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T Cell Receptor (TCR) engineered T Cell therapies (TCR-TS), a modality that holds the potential to generate transformative responses in patients with solid tumors. The company’s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T Cell Receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-Knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens, and commonly shared tumor-driving neoantigens. T-Knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbrück Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.
Something looks off?